Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 31
- 13F valueReported value at the end of Q2 2026
- $920.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LEXX, Q2 2026
No superinvestor reported holding LEXX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lexaria Bioscience Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2025 (view filing) | Jul 29-30 | 1 day | Bunka ChristopherDirector | PPurchase | +27.5K | $0.9157 | +$25.2K | +10.8%281.9K after | 2 lots |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | McKechnie William EdwardDirector | PPurchase | +5.00K | $0.91 | +$4.55K | +37.9%18.2K after | |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Docherty John MartinPresident & CSO | PPurchase | +5.38K | $0.93 | +$5.00K | New position5.38K after | |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Carle VanessaSecretary | PPurchase | +750 | $0.91 | +$682.5 | New position750 after | |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Christopher RichardChief Executive Officer | PPurchase | +15.0K | $0.91 | +$13.7K | +30.0%65.0K after | |
| Dec 3, 2024 (view filing) | Dec 2-3 | 1 day | Christopher RichardChief Executive Officer | PPurchase | +50.0K | $2.36 | +$118.2K | New position50.0K after | 2 lots |
| Aug 13, 2024 (view filing) | Aug 12 | 1 day | Turkel Catherine C.Director | PPurchase | +1.60K | $3.13 | +$5.01K | +106.7%3.10K after | |
| Aug 1, 2024 (view filing) | Jul 31 | 1 day | Carle VanessaSecretary | SSale | −2.57K | $4.00 | −$10.3K | −100.0%0 after | |
| Feb 27, 2023 (view filing) | Feb 9 | 18 daysLate | Turkel Catherine C.Director | PPurchase | +1.50K | $2.84 | +$4.26K | New position1.50K after | |
| Oct 18, 2022 (view filing) | Oct 14 | 4 days | Downey GregoryChief Financial Officer | PPurchase | +121 | $2.09 | +$252.89 | +6.6%1.95K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Lexaria Bioscience Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Invenomic Capital Management LP | 345,685 | $193.6K | 0.01% | −96,616−21.8% | Reduced |
| Vanguard Capital Management LLC | 298,436 | $167.1K | 0.00% | +76,143+34.3% | Added |
| Geode Capital Management, LLC | 250,415 | $140.3K | 0.00% | −43,742−14.9% | Reduced |
| Citadel Advisors LLC | 156,945 | $87.9K | 0.00% | +143,432+1,061.4% | Added |
| Toronto Dominion Bank | 100,013 | $56.1K | 0.00% | −40,000−28.6% | Reduced |
| Vanguard Fiduciary Trust Co | 94,166 | $52.7K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 65,049 | $36.0K | 0.00% | +46,584+252.3% | Added |
| UBS Group AG | 46,966 | $26.3K | 0.00% | −5,742−10.9% | Reduced |
| Northern Trust Corp | 39,825 | $22.3K | 0.00% | +21,436+116.6% | Added |
| State Street Corp | 39,301 | $22.0K | 0.00% | 00.0% | Unchanged |